TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 08/13/20

Thinly traded micro cap TFF Pharmaceuticals (NASDAQ: TFFP ) rallies  24%  after hours in reaction to its agreement with privately held UNION therapeutics A/S potentially granting the latter an exclusive global license to its Thin Film Freezing (TFF) technology used in combinati...

Aims to accelerate development and commercialization of dry powder forms of niclosamide as a new potential treatment for COVID-19 Agreement provides for UNION therapeutics’ potential payment of development, regulatory and sales-related milestone payments of up to $210 million as...

Enters into worldwide license agreement with UNION Therapeutics for its Thin Film Freezing technology in combination with niclosamide Closes on $25.9 million private financing to further advance its technology platform for inhalable drug products, vaccines, biologics and botanicals ...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has entered into a definitive agreement with a sy...

Company to hold conference call and webcast at 4:30 PM EDT TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today a...

Phase 1 repeated dosing of Voriconazole Inhalation Powder of up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing...

Scientists at The University of Texas at Austin report on the use of Thin Film Freezing technology to deliver remdesivir through dry powder inhalation TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovativ...

First dosing of Tacrolimus Inhalation Powder initiates development program for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection Phase 1 topline data indicates safety of single doses of Voriconazole Inhalation Powder up to 80...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the U.S. Food and Drug Administration (FDA) has gran...

The following slide deck was published by TFF Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...